Calistoga Pharmaceutical drugs, Corporation, the best choice in the introduction of isoform-selective PI3 kinase inhibitors for treating cancer and inflammatory illnesses, today introduced the presentation of information showing the Company’s dental, p110δ(delta) selective PI3 kinase inhibitor CAL-101 has broad preclinical anti-tumor activity against a variety of hematologic malignancies. Data were presented within an dental presentatiSeparate
(Read More…)
Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. “J Transl Med. 2011 May ” BACKGROUND: A molecular linkage in between the MAPK and also the LKB1-AMPK power sensor pathways suggests that blended MAPK oncogene inhibition and
(Read More…)
Workman P, Clarke PA, Raynaud F “Cancer research” 2010 The phosphatidylinositide 3-kinase (PI3K) pathway is rather commonly activated in a wide array of human cancersand is particularly a serious motivator in oncogenesis. One of several class I lipid kinase people in the PI3K family, p110alpha, has become the most commonly mutated kinasewithin the human genome.
(Read More…)
Follow @selleckchem on twitter.
